Expression of vascular endothelial growth factor and angiopoietin-2 in myeloma cells

Haematologica

Volumn 88, Issue 1, 2003, Pages 113-115

  Uneda, Shima ^a   Matsuno, Fumihiko ^a   Sonoki, Takashi ^a   Tniguchi, Izumi ^a   Kawano, Fumio ^b   Hata, Hiroyuki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

Angiogenesis; Angiopoietin; Multiple myeloma; VEGF

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOPOIETIN 2; MESSENGER RNA; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; TUMOR MARKER; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MYELOMA CELL; PROGNOSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; LETTER; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PLASMA CELL;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-2; ENDOTHELIAL GROWTH FACTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037311029     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
2. Di Raimondo F,Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-5.
3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
4. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002;116:796-802.
5. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
6. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60.
7. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, et al. Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001;61:6248-54.
8. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
9. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.